The pronounced increase observed in Braak V-VI cases was also observed previously [44], and the present results, together with the marked increase in A+MTL+N+ + participants, further corroborates preceding findings by highlighting the late nature of plasma NTA-tau as an AD biomarker. This evidence concerns the gene MAPT and Alzheimer disease.